Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31451983 | 0.85 | KMT2A (0.45) | KMT2AMEN1PABPC1CA12CA1 | |
| SCHEMBL31452066 | 0.83 | ALDH1A1 (0.43) | KMT2AMEN1PABPC1TP53CA12 | |
| SCHEMBL31452100 | 0.82 | MEN1 (0.41) | KMT2AMEN1PABPC1TP53CA12 | |
| SCHEMBL31452096 | 0.82 | MEN1 (0.44) | KMT2AMEN1PABPC1CA12CA1 | |
| SCHEMBL31452072 | 0.82 | MEN1 (0.41) | KMT2AMEN1PABPC1CA12CA1 | |
| SCHEMBL31452056 | 0.82 | MEN1 (0.56) | KMT2AMEN1PABPC1CA12CA1 | |
| SCHEMBL31451975 | 0.81 | PTGER4 (0.35) | ALDH1A1PTGER4 | |
| SCHEMBL31452105 | 0.80 | MEN1 (0.44) | KMT2AMEN1PABPC1CA12CA1 | |
| SCHEMBL31452009 | 0.79 | MEN1 (0.42) | KMT2AMEN1PABPC1CA12CA1 | |
| SCHEMBL31452121 | 0.79 | MEN1 (0.43) | KMT2AMEN1PABPC1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066371-A1 | FLUOROALKOXYALKYLENE-DIHYDROIMIDAZO[5,1-D]TETRAZINONE COMPOUNDS AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | MODIFI BIOSCIENCES, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2025034537-A1 | FLUOROALKOXYALKYLENE-DIHYDROIMIDAZO[5,1-D]TETRAZINONE COMPOUNDS AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | MODIFI BIOSCIENCES, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066371-A1 | FLUOROALKOXYALKYLENE-DIHYDROIMIDAZO[5,1-D]TETRAZINONE COMPOUNDS AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | PKD1, APC, VHL | KMT2A 2741/4885MEN1 1199/4885PABPC1 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.